Daclizumab trial for relapsing-remitting MS begins
Daclizumab trial for relapsing-remitting MS begins
Active Comparator Study Designed to Examine the Safety and Efficacy of Daclizumab Formulated for Monthly Subcutaneous Dosing.
Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to to interferon beta-1a (Avonex(R)) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).. [Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1502]
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post